NCT06090318 2023-10-19
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Rain Oncology Inc
Phase 1/2 Withdrawn
Rain Oncology Inc
Case Comprehensive Cancer Center
University of Southern California
University College, London